Previous Article | Next Article ![]()
Journal of Clinical Microbiology, March 2008, p. 1081-1089, Vol. 46, No. 3
0095-1137/08/$08.00+0 doi:10.1128/JCM.01740-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Lawrence Livermore National Laboratory, Livermore, California,1 Institute for Animal Health, Pirbright Laboratory, Pirbright, Woking, Surrey GU24 0NF, United Kingdom2
Received 31 August 2007/ Returned for modification 22 October 2007/ Accepted 4 January 2008
|
|
|---|
|
|
|---|
Real-time PCR is widely used by diagnostic laboratories to complement or as a replacement for more traditional detection methods. Two independent real-time RT-PCR (rRT-PCR) assays for FMD laboratory diagnosis target the ribosomal entry site of the 5'-untranslated region (5'UTR) (30) and the viral RNA polymerase gene (3D) (4) on the highly variable FMDV genome. The 5'UTR and 3D rRT-PCR assays initially were compared to each other prior to their implementation in Australia (3). A subsequent in-depth comparative evaluation was conducted to further evaluate the effectiveness of these assays, which demonstrated a higher diagnostic sensitivity of the rRT-PCR assays compared to that of VI and/or Ag-ELISA, particularly when both assays were used in combination (14). Both assays are used routinely in combination at the Food and Agriculture Organization of the United Nations, World Reference Laboratory (FAO WRL), for FMD. rRT-PCR assays also have been reported for the detection of other viruses that cause vesicular disease of livestock, including swine vesicular disease (SVD) (29), vesicular stomatitis (VS) (11, 28), and vesicular exanthema of swine (VES) (31), or symptomatic look-alike diseases, including bluetongue (13, 27, 33), bovine viral diarrhea (1, 2, 20, 22, 39), malignant catarrhal fever (37), and parapox (26).
Fluorescent probes for rRT-PCR detection have broad emission spectra that limit the multiplexing capacity to the four or five discrete optical channels typically present in most commercial real-time PCR instruments. Therefore, simultaneous testing for FMDV and look-alike disease viruses by rRT-PCR would require many assays to be run in parallel, thereby increasing the demand on instrumentation and reagents, which escalates costs. A single multiplexed screening test that simultaneously detects and differentiates FMDV from look-alike disease viruses is desirable. Such a test could facilitate the rapid and cost-effective screening of suspect FMD field samples for laboratory differential detection, targeted FMD surveillance, or embedded foreign animal disease surveillance while conducting routine testing for diseases that are endemic to those areas.
Luminex xMAP technology is a multiplexed high-throughput detection system (38) with many applications for nucleic acid detection (6). The Luminex array offers up to 100 independent channels and uses microspheres (5.6 µm in diameter) embedded with various ratios of two fluorescent dyes. User-defined surface modifications can include the addition of oligonucleotides, antibodies, peptides, or other macromolecules. Typically, a mixed suspension of functionalized microspheres is mixed with the sample to bind analytes, which then are labeled with a fluorescent reporter and analyzed using a specialized flow cytometer. For each microsphere channel, the signal resulting from the bound fluorescent reporter is measured and reported as the median fluorescence intensity (MFI), which can be compared to a cutoff value to provide end point detection with qualitative results. Recent nucleic acid applications of the Luminex array include the detection and differentiation of classical swine fever virus from other pestiviruses (5) and the typing of human respiratory viruses (18, 19, 21, 23), human papillomavirus (10, 32), and human influenza A virus (40).
This report describes a novel multiplexed RT-PCR (mRT-PCR) microsphere array assay for the differential detection of FMDV from look-alike disease viruses. The development, optimization, and analytical evaluation of this multiplex assay will be reported separately. The primary purpose of this study was to evaluate the diagnostic performance of the mRT-PCR assay for the detection of FMDV using a panel of suspect field samples. The diagnostic sensitivities of the 3D and 5'UTR FMDV assays in mRT-PCR format were compared to that of rRT-PCR using VI combined with Ag-ELISA as the reference method. The detection of look-alike disease viruses in suspect FMD field samples also is reported.
|
|
|---|
10% (wt/vol) suspension in phosphate buffer (0.04 M, pH 7.6). The epithelial suspensions (ES) were centrifuged, and the supernatant was collected and then stored at –80°C. The FMDV serotype was determined by conducting an Ag-ELISA (8) on the original ES or after viral propagation in cell culture. Samples of look-alike viruses from the FAO WRL for FMD collection included SVD virus (SVDV), VES virus (VESV), San Miguel sea lion virus, caliciviruses isolated from a variety of species (including cetacean, bovine, feline, reptilian, and skunk species), and VS virus (VSV). Nucleic acid extraction. Total nucleic acid was extracted from each ES by an automated procedure using a MagNA Pure LC (Roche, United Kingdom) as previously described (14, 35). Extracted samples (40 µl) were aliquoted (three samples of 13 µl each), stored at –80°C, and thawed once just before use.
rRT-PCR. Previously reported protocols for the individual 3D (4) and 5'UTR (34) rRT-PCR assays were modified for use in this study. Briefly, 25-µl reaction mixes (SuperScript III platinum one-step quantitative RT-PCR system [Invitrogen]) containing 20 pmol of each primer, 7.5 pmol of dual-labeled TaqMan probe, and 5 µl total nucleic acid were prepared in an optical reaction plate (Stratagene, Amsterdam, The Netherlands). For both targets, RT-PCR amplification was performed in an Mx4000 multiplex quantitative PCR system (Stratagene) as described previously (34).
mRT-PCR assay design. A schematic depiction of the mRT-PCR assay is shown in Fig. 1. The RT-PCR uses 18 biotinylated forward and unmodified reverse primer sets (17 for detection, 1 as a control). The sequences that comprise the multiplex assay are shown in Table 1. The multiplex assay was designed to detect and differentiate FMDV from SVDV, VESV, bovine viral diarrhea virus (BVDV), bluetongue virus (BTV), parapoxviruses (PPOX; orf virus, pseudocowpox virus, and bovine papular stomatitis virus), and bovine herpesvirus type 1 (BHV-1). Primer-probe sequences for FMDV (4, 30) and BVDV (7, 22) were based on the work of others and adapted to the current multiplex format. All other sequences were designed at the Lawrence Livermore National Laboratory using an approach that was described previously (36). Additional computational analyses were performed to ensure the specificity and reliability of all available data, including a BLAST-based comparison of each primer-probe set as a triplet against all sequences in GenBank to identify the targets that are predicted to produce a PCR or TaqMan reaction at 57°C for primer annealing and 67°C for probe annealing, where temperatures are derived from Primer 3 oligonucleotide melting point calculations. Optimal candidate primer-probe sets were forwarded to the bench-screening phase for further down-selection. Amplicon sizes ranged from 95 to 349 bp.
![]() View larger version (18K): [in a new window] |
FIG. 1. Schematic of the mRT-PCR assay. In the presence of target nucleic acid, the biotinylated forward primer is extended during the PCR. The PCR product is hybridized to the microsphere array, at which point the extended forward primer binds to the complementary probe-labeled microsphere. The complex is labeled with a fluorescent reporter (SAPE) and then analyzed using a Bio-Plex flow cytometer. The fluorescence (570 nm) of bound reporter molecules is measured, and the MFI is calculated for each microsphere class and then compared to a cutoff to indicate the presence or absence of a target nucleic acid sequence in a sample.
|
|
View this table: [in a new window] |
TABLE 1. Primer and probe sequences of the mRT-PCR assaya
|
Coupling of probe oligonucleotides to microspheres. xMAP multianalyte COOH microspheres (Luminex Corp., Austin, TX) were covalently coupled to probe oligonucleotides using carbodiimide activation based on the manufacturer's protocol. Briefly, stock microspheres (1 ml; 1.25 x 107 microspheres) were vortexed for 30 s, sonicated for 60 s, and centrifuged at 8,000 x g for 5 min, and then the supernatant was removed. The microspheres then were resuspended in MES (50 µl, 0.1 M, pH 4.5), vortexed, and sonicated. Probe (10 µl; 50 µM in MES) was added, and the mixture was vortexed. An aqueous solution of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC; 5 µl, 10 mg/ml) was added, vortexed, and then gently agitated for 30 min in the dark. A second aliquot of EDC (5 µl, 10 mg/ml) was added, vortexed, and then gently agitated for 30 min in the dark. Tween 20 (1 ml, 0.02% [vol/vol]) was added, vortexed, and centrifuged, and the supernatant was removed, after which the washing was repeated using sodium dodecyl sulfate (1 ml, 0.1% [mass/vol]) and then TE buffer. The probe-conjugated microspheres were resuspended in TE buffer (250 µl), vortexed, and then stored at 4°C in the dark.
Microsphere mixture. A 21-plex microsphere suspension was prepared by combining individual stock suspensions (9 µl/class) with Tris-NaCl buffer (3 ml; 0.1 M Tris, 0.2 M NaCl, 0.05% [vol/vol] Triton X-100, pH 8.0; Teknova). The mixture was vortexed and then enumerated using the Bio-Plex workstation (Bio-Rad, CA), targeting approximately 150 microsphere counts per class in 40 s. If required, additional microspheres from the individual stocks were added to ensure that the concentrations of all classes were approximately equal.
mRT-PCR amplification.
Each field sample was analyzed in duplicate by the multiplex assay. Amplification was performed using a one-step RT-PCR kit (SuperScript III one-step RT-PCR system with platinum Taq DNA polymerase; Invitrogen). The reaction volume of 25 µl was comprised of nuclease-free water (0.95 µl), primer mix (3.6 µl), SuperScript III 2x reaction mix (12.5 µl), MgSO4 (0.95 µl, 50 mM; Invitrogen), SuperScript III RT/platinum Taq mix (1 µl), internal control armored RNA (1 µl;
100 copies), and template (5 µl). The internal control armored RNA was lysed by being heated to 70°C for 4 min prior to being added to the mix. The final concentration of each primer and MgSO4 was 0.4 µM and 3.5 mM, respectively. The mRT-PCR thermal cycling protocol was 55°C for 30 min, 95°C for 2 min, and then 35 cycles of 95°C for 15 s, 60°C for 30 s, and 72°C for 15 s, followed by 72°C for 2 min with a final hold at 4°C.
Microsphere array hybridization. A wash-assay format was adopted to reduce the variability of the response caused by the nonspecific hybridization of PCR products and fluorescent label. In a 96-well plate, RT-PCR product (1 µl) was added to a mixed suspension of probe-conjugated microspheres (22 µl) and then placed in a thermal cycler and subjected to 95°C for 2 min, 55°C for 5 min, and then a 4°C hold. Tris-NaCl (100 µl) was added, and the suspension was transferred to a 96-well vacuum filter plate (MABVN 1250 multiscreen filter plate; Millipore). The suspension was vacuum aspirated and washed twice with Tris-NaCl buffer (100 µl for each wash). Stock streptavidin phycoerythrin (SAPE; 1 mg/ml; Caltag Laboratories) was diluted with Tris-NaCl to a working concentration of 3 µg/ml. SAPE (60 µl, 3 µg/ml) was added, and the suspension was incubated in the dark for 5 min. The suspension was vacuum aspirated, washed once with Tris-NaCl (100 µl), resuspended in Tris-NaCl (100 µl), and then transferred to a 96-well round-bottom plate for fluorescent detection. Nucleic acid extraction, PCR assembly, and PCR amplification were conducted in separate rooms. Likewise, hybridization and Bio-Plex detection were performed together in a separate room to minimize the likelihood of PCR contamination by amplicons.
mRT-PCR detection. Fluorescence detection of the processed microsphere suspension array was achieved using a Bio-Plex workstation set to count a minimum of 100 events per microsphere class in a 50-µl Bio-Plex sample volume. The Bio-Plex workstation is a specialized dual-laser flow cytometer integrated with an XY microplate platform configured to analyze Luminex xMAP microspheres in a 96-well plate format. The reporter photomultiplier tube voltage was calibrated on the low setting with background subtraction enabled. The Bio-Plex workstation was validated and calibrated per the manufacturer's instructions. The resolution of the MFI was 0.5 U for all channels.
mRT-PCR assay controls.
The multiplex assay incorporates four control channels integral to each reaction that are used to verify the assay's integrity. The negative control (NC) is a microsphere conjugated to a Thermotoga maratima-derived oligonucleotide sequence (MT-7) that serves as a nonspecific binding control in the mRT-PCR assay, and its response should remain consistently low (MFI
80). The fluorescence control (FC), biotinylated MT-7, confirms that fluorescent labeling with SAPE occurred, and it should exhibit a high response (MFI > 1,000). The instrument control (IC) comprises a Cy3-labeled MT-7 conjugate. As Cy3 and SAPE have similar fluorescence excitation and emission wavelengths, the IC confirms the proper function of the reporter optics within the Bio-Plex flow cytometer (MFI > 500). Armored RNA served as an end-to-end amplification control (AC) to reduce the probability of a false-negative result and is utilized at low concentrations (100 copies/reaction) to generate a low-level response (MFI
20) that minimizes its competition with detection channels. The armored RNA (XenoRNA-01; Ambion, Austin, TX) is a proprietary 1,070-nucleotide RNA transcript consisting of unique nucleotide sequences that possess no significant homology to the current annotated sequences in commonly used sequence databases, including NCBI, Affymetrix, and Rosetta. Primers and probe-labeled microspheres for the AC are included in the multiplex primer mix and microsphere suspension, respectively.
mRT-PCR assay integrity.
Minimum bead count quotas and control channel responses were used to verify the integrity of the detection channel responses, which minimizes the likelihood of false-positive and false-negative results caused by operator error, instrument malfunction, nonspecific hybridization, or PCR inhibition. The responses of all detection channels are checked against preestablished cutoffs, after which the results are defined as mRT-PCR positive, negative, or inconclusive. For each sample, the MFI of each control bead class was checked against a cutoff value. A given result was considered invalid if the MFI value of the IC, NC, or FC control was out of range or if both the response of the AC was <20 and no detection channels exceeded the cutoff. Results were considered valid when the AC was <20 and any detection channel exceeded the cutoff. The AC response can be diminished by a strong positive response on a detection channel caused by competition in the RT-PCR. If the responses of all control channels are acceptable, the numbers of beads counted for control and detection channels are checked (
40 beads per channel). If a low bead count for any control channel occurred, all results for that sample were considered invalid. A low bead count on a given detection channel was considered an invalid result for the channel in question.
Data analysis. Raw data exported from the Bio-Plex instrument were imported into MATLAB (MathWorks) and then analyzed using Microsoft Excel. If at least one result from a duplicate sample analysis exceeded the cutoff, the sample was assigned as mRT-PCR positive. Receiver operating characteristic (ROC) plots (24) were generated using a custom MATLAB program. Published guidelines (25) were followed for the calculations of diagnostic test accuracy and for statistical methods to quantify uncertainty.
Cutoff values.
The mRT-PCR responses for this assay typically are non-Gaussian; therefore, nonparametric methods were used to determine cutoffs. Each channel in the multiplex has a distinct distribution of responses to true-negative samples; therefore, each is assigned its own cutoff value. For each detection channel of the mRT-PCR assay, the responses of true-negative samples were ranked according to magnitude, and then cutoff values were identified as the response (MFI value) that gave a false-positive rate closest to 5% (without exceeding 5%), corresponding to a diagnostic specificity of at least 95% (3D MFI,
6.5; 5'UTR MFI,
5.5). Other mRT-PCR detection channels for the FMD look-alike disease viruses had similar cutoffs. For rRT-PCR, the cutoff was a cycle threshold (CT) of
32 for both 3D and 5'UTR assays (34).
|
|
|---|
![]() View larger version (18K): [in a new window] |
FIG. 2. ROC plots for the 3D and the 5'UTR assays in singleplex rRT-PCR and mRT-PCR formats. True-positive samples (n = 213) representative of all FMDV serotypes and true-negative samples (n = 74) were analyzed. The areas under the curves are the following: 3D rRT-PCR, 0.985; 5'UTR rRT-PCR, 0.942; 3D mRT-PCR, 0.955; and 5'UTR mRT-PCR, 0.773.
|
|
View this table: [in a new window] |
TABLE 2. Performance metrics for the 3D and 5'UTR FMDV assays in rRT-PCR and mRT-PCR formats using independent or combined results
|
|
View this table: [in a new window] |
TABLE 3. Three-way comparison for the combined results of 3D and 5'UTR assays in rRT-PCR and mRT-PCR formats
|
LOD. The LODs of the 3D and 5'UTR assays in mRT-PCR and rRT-PCR formats were compared using serially diluted clinical samples of serotype O or SAT 2 (Fig. 3). At the defined cutoff values, the mRT-PCR LOD was higher than that for rRT-PCR by approximately 5 to 625 times for the 3D assay and 25 to 125 times for the 5'UTR assay, depending on the serotype. The higher LOD of the mRT-PCR therefore caused the loss of diagnostic performance, which was evident in the ROC plots. Further assay optimization hopefully could improve the limits of detection of the 3D and 5'UTR assays in the mRT-PCR format.
![]() View larger version (13K): [in a new window] |
FIG. 3. Comparison of the 3D and 5'UTR assay responses in mRT-PCR and singleplex rRT-PCR formats by consecutive fivefold serial dilutions of three different FMDV true-positive epithelial suspension samples (undiluted to more dilute from right to left). Detection by mRT-PCR was less sensitive than that by singleplex rRT-PCR (approximately 5 to 625 times and 25 to 125 times for 3D and 5'UTR signatures, respectively). Cutoff values for rRT-PCR (CT 32) and mRT-PCR (3D MFI, 6.5; 5'UTR MFI, 5.5) are indicated by the vertical and horizontal dashed lines, respectively. The 5'UTR signature did not respond to the SAT 2 (SAU 4/2000) sample at any dilution in singleplex rRT-PCR or mRT-PCR formats and was omitted from the plot. Error bars indicate ±1 standard deviation of the mean (n = 2) response from the signature in the mRT-PCR format. For rRT-PCR, each sample was analyzed as a singlet (n = 1). Pos., positive; Neg., negative.
|
![]() View larger version (16K): [in a new window] |
FIG. 4. mRT-PCR assay identification of FMDV look-alike disease viruses in suspect FMDV clinical sample submissions. The mRT-PCR assay ruled out FMDV while simultaneously ruling in FMD look-alike disease viruses. (A and B) Multiloci detection of PPOX. (C) BVDV detection in field samples from cattle (UKG 36/94 and UKG 37/94) that tested FMDV negative by virus isolation and rRT-PCR and the simultaneous detection of FMDV and BVDV (HUN 2/72). mRT-PCR cutoffs indicated by the vertical dashed lines were the following: PPOX-1, 7.5; PPOX-3, 9.5; and BVDV, 6.5. The horizontal dashed lines indicate the cutoff for the FMDV 3D assay ( 6.5). Pos., positive; Neg., negative.
|
|
|
|---|
The 3D and 5'UTR assay responses had serotypic bias, a finding that agrees with earlier observations (4, 14). In the mRT-PCR format, the 3D assay was less sensitive for A and C serotypes, whereas the 5'UTR was less effective against SAT serotypes. For all serotypes collectively, the 3D assay was more sensitive than the 5'UTR assay within each format (rRT-PCR 3D and 5'UTR sensitivities, 96.7 and 87.3%, respectively; mRT-PCR 3D and 5'UTR sensitivities, 90.1 and 58.7%, respectively). In an earlier evaluation of the rRT-PCR assays (14), the diagnostic sensitivity of the 3D assay (97.7%) was found to be slightly higher than that of the 5'UTR assay (95.4%). The diagnostic sensitivity increased when the results of the 3D and 5'UTR assays were combined. This is due to the "or" nature of the combination, in which a single mRT-PCR positive result on the 3D or 5'UTR channel generates a combined mRT-PCR positive result. The diagnostic sensitivity of the combined mRT-PCR assay was 93.9%; that of the combined rRT-PCR was 98.1%. The loss of diagnostic sensitivity between rRT-PCR and mRT-PCR, due to a higher LOD, was partially offset by the inherent ability of the multiplex assay to simultaneously screen multiple loci. Conducting parallel rRT-PCR assays showed that combining results from both rRT-PCR assays increased the diagnostic sensitivity by only 1.4% above that of using the 3D rRT-PCR assay results in isolation. As the mRT-PCR is a screening assay that most likely would be used in conjunction with confirmatory tests, potential users may be more tolerant of lower specificity in order to achieve higher sensitivity.
The differential detection of FMDV from look-alike disease viruses, which included single-stranded RNA and double-stranded DNA targets, was demonstrated by testing representative isolates of SVDV, VESV, and VSV. For a diagnostic laboratory, this could produce time and cost savings compared to the time and cost of testing for each disease using singleplex rRT-PCR assays. For veterinarians, the mRT-PCR assay could increase confidence in a sample identified as FMDV negative by simultaneously screening for the presence of look-alike diseases. For networks of veterinary diagnostic laboratories, an mRT-PCR assay could facilitate embedded foreign animal disease surveillance while conducting routine testing for animal disease viruses that are endemic to the area. An interlaboratory evaluation of this multiplex assay recently was conducted in 14 U.S. National Animal Health Laboratory Network laboratories; the results suggested that the mRT-PCR technology could be operated successfully in this setting. The diagnostic performance evaluation for the look-alike disease assays in the mRT-PCR format is under way and will be reported separately.
The mRT-PCR format is compatible with the procedures and instrumentation used for rRT-PCR. The use of a single method to prepare clinical samples for mRT-PCR and rRT-PCR analysis was demonstrated in this study. The mRT-PCR requires the postprocessing of RT-PCR products to the microsphere array, which takes
50 min per 96-well plate using manually operated multichannel pipettes. The 96-well plate format provides convenient interchangeability between manual and automated platforms. With this reagent set, the Bio-Plex flow cytometer analyzed each well in
40 s, or
1 h per 96-well plate. Although the diagnostic sensitivity of the mRT-PCR for FMDV detection is lower than that of the singleplex rRT-PCR, it provides significantly more diagnostic information. With 17 detection channels for seven different viruses, the current prototype panel generates 1,632 individual assay results per 96-well plate. The microsphere suspension array is a versatile platform compatible with many different types of diagnostic tests, including immunological and serological assays, which could increase its utility within a veterinary diagnostic laboratory not only for outbreak response and recovery but also for routine testing for diseases that are endemic to the area. The inherent flexibility of the Luminex array also enables the composition of a given multiplex assay to be altered by simply adding or removing detection channels. Refinements to the first version of the mRT-PCR assay described herein currently are under way, including the development of two species-specific panels for more comprehensive coverage. These new panels incorporate additional assays for other FMDV look-alike diseases. The bovine-specific panel incorporates assays for FMD, malignant catarrhal fever, rinderpest, bluetongue, BHV-1 disease, bovine viral diarrhea, parapox, and VS. The porcine-specific panel includes assays for FMD, SVD, VES, VS, and porcine reproductive and respiratory syndrome.
The material presented represents the position of the authors and not necessarily that of DHS.
Published ahead of print on 23 January 2008. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»